Pfizer Vaccine on Track for Regulatory Review in October
- Pfizer, BioNTech have deal to supply 100 million doses to U..S
- Some analysts expect a vaccine to be approved by November
This article is for subscribers only.
Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.